There are currently 36 active clinical trials seeking participants for Hodgkin Lymphoma research studies. The states with the highest number of trials for Hodgkin Lymphoma participants are New York, California, Texas and Michigan.
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
NCT05615636
Recruiting
To learn if giving mosunetuzumab in combination with polatuzumab vedotin, tafasitamab, and lenalidomide can help to control relapsed/refractory FL and DLBCL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Hodgkin Lymphoma, B-Cell Lymphoma, Relapsed B-cell NHL
Register for Updates
Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas
NCT05565417
Recruiting
This is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in which IMT-009 will be administered by the intravenous (IV) route to participants with solid tumors or lymphomas. The main goals of this study are to: * Find the recommended dose of IMT-009 that can be safely given to participants * Learn more about the side effects of IMT-009 * Learn more about pharmacokinetics of IMT-009 * Learn more about the effectiveness of IMT-009 * Learn more about different pharmac... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Site 9618, Tucson, Arizona +9 locations
Conditions: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Small Bowel Cancer, Esophageal Cancer, Colorectal Cancer, Diffuse Large B Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Follicular Lymphoma
Register for Updates
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
NCT05092451
Recruiting
The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma. Immune system cells (such as NK cells) are made by the body to attack foreign or cancerous cells. Researchers think that NK cells you receive from a donor may react against cancer cells in your body, which may help to control the disease.
Gender:
ALL
Ages:
Between 12 years and 80 years
Trial Updated:
03/11/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: B-Cell Lymphoma, Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), Multiple Myeloma, Plasma Cell Leukemia, Hodgkin Lymphoma, T-cell Non-Hodgkin's Lymphoma/ T-cell Acute Lymphoblastic Leukmeia, Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia, Blastic Transformation of Chronic Myeloid Leukemia, Germ Cell Tumors
Register for Updates
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
NCT06059391
Recruiting
This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV) infection in patients undergoing hematopoietic stem cell transplant. The CMV-MVA Triplex vaccine works by causing an immune response in the donors body to the CMV virus, creating immunity to it. The donor then passes that immunity on to the patient upon receiving the stem... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/06/2025
Locations: City of Hope Medical Center, Duarte, California +2 locations
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
Register for Updates
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
NCT04685616
Recruiting
RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New Zealand. Trial 2 will be led by the Canadian Cancer Trials Group (CCTG) and conducted in North America, with CCTG the regulatory sponsor in Canada, and University of Miami the regulatory sponsor and IND holder in the US. Datasets from Trial 1 and Trial 2 will... Read More
Gender:
ALL
Ages:
Between 16 years and 69 years
Trial Updated:
03/04/2025
Locations: Stanford University - (Stanford Cancer Institute), Stanford, California +49 locations
Conditions: Hodgkin Lymphoma
Register for Updates
Natural Killer (NK) Cells in Combination with Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
NCT05400122
Recruiting
One of the ways that cancer grows and spreads is by avoiding the immune system.NK cells are immune cells that kill cancer cells, but are often malfunctioning in people with colorectal cancer and blood cancers. A safe way to give people with colorectal cancer and blood cancers fresh NK cells from a healthy donor has recently been discovered. The purpose of this study is to show that using two medicines (vactosertib and IL-2) with NK cells will be safe and will activate the donor NK cells. NK cell... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloproliferative Syndrome, Plasma Cell Myeloma, Gastric Cancer, Esophageal Cancer, Esophagus Cancer, Gastric Cancer, Metastatic, Unresectable Esophageal Cancer, Metastatic Esophageal Cancer
Register for Updates
PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
NCT05922904
Recruiting
To learn about the effects of brentuximab vedotin and pembrolizumab in combination with doxorubicin and dacarbazine when given to patients who have Stage II cHL with bulky mediastinal disease or advanced cHL (Stage III or IV) and who have not received treatment for the disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Hodgkin Lymphoma
Register for Updates
AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.
NCT06137144
Recruiting
This study is designed to evaluate the safety, tolerability, PK and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.
Gender:
ALL
Ages:
15 years and above
Trial Updated:
02/25/2025
Locations: Research Site, Miami, Florida +19 locations
Conditions: Lymphoma, Non-Hodgkin, Hodgkin Lymphoma
Register for Updates
A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma
NCT05705531
Recruiting
This study assesses how blood cell growth patterns (clonal hematopoiesis), relates to heart health or cardiovascular disease (CVD) after treatment in patients with Hodgkin lymphoma. In some patients, cancer treatment at a young age may lead to later complications, including problems with heart health. Checking for blood cell growth patterns called therapy-related clonal hematopoiesis (t-CH) can help predict who might be at risk for heart health problems after Hodgkin lymphoma treatment. If docto... Read More
Gender:
ALL
Ages:
Between 7 years and 40 years
Trial Updated:
02/11/2025
Locations: USA Health Strada Patient Care Center, Mobile, Alabama +22 locations
Conditions: Hodgkin Lymphoma, Cardiovascular Disorder, Clonal Hematopoiesis
Register for Updates
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
NCT03755804
Recruiting
This is a phase II study using risk and response-adapted therapy for low, intermediate and high risk classical Hodgkin lymphoma. Chemotherapy regimens will be based on risk group assignment. Low-risk and intermediate- risk patients will be treated with bendamustine, etoposide, Adriamycin® (doxorubicin), bleomycin, Oncovin® (vincristine), vinblastine, and prednisone (BEABOVP) chemotherapy. High-risk patients will receive Adcetris® (brentuximab vedotin), etoposide, prednisone and Adriamycin® (doxo... Read More
Gender:
ALL
Ages:
25 years and below
Trial Updated:
02/06/2025
Locations: Lucile Packard Children's Hospital Stanford University, Palo Alto, California +7 locations
Conditions: Hodgkin Lymphoma
Register for Updates
Use of Transcranial Photobiomodulation to Improve Cognition and Self-Reported Outcomes in Survivors of Childhood Cancer
NCT05550948
Recruiting
Survivors of childhood cancer are at greater risk for long-term cognitive impairments that include attention, executive function, intelligence, memory, and processing speed. The participants are a survivor of acute lymphoblastic leukemia (ALL) or Hodgkin's lymphoma (HL). Because of your treatment the participant may have developed trouble with thinking and learning. Primary Objective To evaluate the feasibility of using home-based tPBM paired with remote cognitive training to improve cognitive... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: ALL, Hodgkin Lymphoma, Cancer, Survivorship
Register for Updates
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
NCT01351545
Recruiting
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
Gender:
ALL
Ages:
All
Trial Updated:
01/23/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +140 locations
Conditions: Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Severe Aplastic Anemia, Autoimmune Diseases
Register for Updates